Anticoagulation After GI Bleeding Pilot Study and Registry

Inclusion Criteria

• •1. Male or female subjects aged 18 years or older
• •2. Hospitalized with acute major non-variceal GI bleeding (defined as per ISTH criteria) while receiving OAC therapy (warfarin or DOAC).
• •3. OAC therapy discontinued for current acute GI bleed and not yet resumed
• •4. Ongoing indication for long-term anticoagulation of atrial fibrillation (moderate to high risk of stroke/systemic embolism with CHA2DS2VASc score of 3 or higher) or VTE (as per clinical care team)
• •5. Planned to resume DOAC post-bleed
• •6. At moderate to high risk of re-bleeding as per clinical care team
• •7. Clinical hemostasis achieved as per clinical care team
• •8. Able and willing to comply with follow-up examinations contained within the consent form